^
    Back
    Association details:
    Biomarker:CD70 expression
    Cancer:Uterine Corpus Leiomyosarcoma
    Drug:JNJ-0631 (CD70-targeted antibody-drug conjugate)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Am J Obstet Gynecol
    Title:

    CD70 antibody-drug conjugate as a potential therapeutic agent for uterine leiomyosarcoma

    Published date:
    08/18/2020
    Excerpt:
    Uterine leiomyosarcoma tumors highly express CD70 and targeted therapy with CD70-ADC may have a potential therapeutic implication in the treatment of uterine leiomyosarcoma.
    DOI:
    10.1016/j.ajog.2020.08.028